Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2100
Peer-review started: November 28, 2020
First decision: January 24, 2021
Revised: February 2, 2021
Accepted: March 9, 2021
Article in press: March 9, 2021
Published online: March 26, 2021
Processing time: 117 Days and 10.2 Hours
Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP.
Core Tip: Ion channel drugs are the treatment of choice for neuropathic pain; however, non-adherence to these drugs makes pain relief unsatisfactory. The Chinese Association for the Study of Pain organized first-line pain management experts from across China to write an expert consensus on the guidelines for usage of ion channel drugs. Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A (BLA), pregabalin, and gabapentin.
- Citation: Xiao H, Ma K, Huang D, Liu XG, Liu TH, Liu Q, Liu GZ, Song T, Tao W, Wu DS, Wang YX, Yang XQ, Zhang XM, Liu H, Liu YQ. Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain. World J Clin Cases 2021; 9(9): 2100-2109
- URL: https://www.wjgnet.com/2307-8960/full/v9/i9/2100.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i9.2100
Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system[1]; it has a complex pathogenesis. The prevalence of NPP in the general population is as high as 8.0%[2]. Based on these data, there are about 90 million NPP patients in China, and the incidence of NPP is increasing gradually.
Currently, the main treatment for NPP is clinical drug therapy, of which the most common drugs include anticonvulsants, antidepressants, opioid analgesics, and N-methyl-D-aspartate (NMDA) antagonists. Most are ion channel drugs, but the response rate is only about 46.3%[3]. Due to the complexity of NPP etiology/pathogenesis, diverse nature of pain, duration of disease and pain ranging, a reasonable combination therapy of different ion channel drugs is an effective way to improve the clinical efficacy currently. To regulate treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain (CASP) organized first-line pain management experts from China to write an expert consensus as a reference for the use of ion channel drugs.
The clinical manifestation of NPP includes decreased pain threshold, increased pain response and spontaneous pain, which are mainly related to peripheral and central sensitization. Peripheral sensitization refers to the abnormal expression of voltage-dependent ion channels in primary afferent neurons, leading to increased excitability and increased pain signals. The central one refers to the continuous enhancement of synaptic transmission efficiency on the pain pathway, then amplify the pain signals. The abnormal expression of ion channels induces NPP. There are currently two types of ion channel drugs in clinical use: sodium channel blockers and calcium channel modulators. Sodium channel blockers are represented by carbamazepine, lidocaine, and BLA. They block different types of voltage-dependent sodium channels and inhibit overexcited sensory neurons. Calcium channel adjusting section comprises gabapentin and pregabalin, which selectively inhibit synaptic transmission of pain, to alleviate NPP without directly blocking effects on the calcium channel. The α2δ1 subunit located in the presynaptic calcium channel of the spinal dorsal horn is upregulated during NPP, resulting in increased release of neurotransmitters and enhanced synaptic transmission of pain. Gabapentin and pregabalin bind to this subunit, downregulating it and exerting analgesic effects. In short, by inhibiting the peripheral sensitization and central sensitization, ion channel drugs affect NPP. Sodium channel blockers and calcium channel modulators have anticonvulsant effects as well.
(1) Individualized therapy: It is necessary to pay attention to the wide dose difference to achieve the effective analgesia of the patient. When a drug is not effective, the resistance occurs or effective duration shortened after long-term treatment, it is not advisable to change the drug easily. It is advised to increase the dose to obtain satisfactory results without serious side effects, but care should be taken to avoid exceeding the toxic threshold; (2) Timely administration: Take drugs with proper interval based on their onset time, to maximize analgesia effect; (3) Oral administration: Choose oral, non-invasive approach medicine as possible; (4) Closely observe the medication’s onset time, effective duration, degree of analgesic effect, and side effects to ensure an adequate course of treatment; and (5) Adjust the dosage of drugs according to the state of illness: Combination therapy should be considered when the effect of the single drug is not effective.
Mechanism and characteristics of sodium channel drugs: The sodium ion channel is a transmembrane glycoprotein on the cell membrane, which selectively allows sodium to pass through the membrane. Sodium channel antagonist agents can eliminate or alleviate acute pain, inflammatory pain, and NPP and effectively improve the symptoms of hyperalgesia of NPP[4].
Typical drugs of sodium channel antagonists: Representative drugs for sodium ion channel antagonists include carbamazepine, oxcarbazepine, lidocaine, and BLA. Carbamazepine works by inhibiting cell membrane sodium ion channels, reducing neurotransmitter release, and reducing nerve cell excitability. In addition, it also acts on gamma-aminobutyric acid (GABA) receptors, interferes with glutamate functions through NMDA receptors, and regulates central sensitization. The mechanism of oxcarbazepine is by blocking voltage-dependent sodium channels in the brain, stabilizing the neuronal cell membrane, inhibiting repetitive firing of neurons, reducing the release of synaptic impulses, and reducing high voltage-activated calcium currents in the striatum and cortical neurons, thereby reducing the glutamate-induced transmission of cortical striatum synapses[5]. Both mechanisms may be involved in the treatment of neuralgia by oxcarbazepine. Some studies have also suggested that oxcarbazepine may play a role by inhibiting substance-P mediated pain transmission[6].
Lidocaine is a typical sodium channel antagonist; it inhibits sodium ion channels and blocks the action of increased excitability of central neuron, thereby impacting peripheral and central endings and having analgesic effects[7].
BLA can state dependently inhibit voltage-gated sodium channels. Second, BLA may have anti-inflammatory and analgesic effects through many methods including lowering serum prostaglandin E2 levels, regulating serotonin (5-hydroxytryptamine) levels in the brain and stimulating the expression of dynorphin A in spinal microglia, relieving beta- endorphin inhibition which raises pain thresholds.
Pharmacokinetics, pharmacodynamics, and physicochemical properties of sodium ion channel antagonists: Carbamazepine is commonly used as anticonvulsant drugs. Its gastrointestinal absorption is slow and irregular. Due to dose-dependent induction by itself or other enzymes as well as age, comorbidities, combination therapy, etc., it appears to have high variance of individual pharmacokinetics (PKs)[8]. The formulation and food intake do not affect the rate and speed of absorption. After taking a single dose of carbamazepine, peak plasma concentration reached within 12 h, peak concentration reached 4-5 h (0.5-25 μg/mL) after oral administration of 400 mg, and steady-state plasma concentration was reached within 1-2 wk. It has been recommended that the carbamazepine plasma concentration of 4-12 μg/mL is “effective” in adults[9]. Carbamazepine is metabolized by the liver. Epoxidization is its major metabolic pathways, and it is metabolized by cytochrome P450 3A4 to pharmacologically active 10, 11- epoxy carbamazepine. Protein binding rates of these two substances are 76% and 48%-53%. They can pass through the placental barrier and be secreted with lactating. Carbamazepine’s t1/2 is related to the duration of treatment, 25-65 h for a single administration, and 12-17 h for long-term administration[10]. Its half-life of children is significantly shortened, and there is no change in the PKs in elderly patients. PK data in patients with liver or renal disease are still insufficient (Table 1).
| Sodium channel blockers | Calcium channel modulators | |||||
| Carbamazepine | Oxcarbazepine | Lidocaine, by iv | BLA | Pregabalin | Gabapentin | |
| T max | Within 12 h | 4.5 h | 5 min | 1 h | 3 h | |
| C max | 0.5-25 μg/mL | 31.5 μmol/L | 2-5 mg/lanalgesic use | 3.83-9.46 μg/mL | 2.7-2.99 mg/L | |
| t1/2 | 25-65 h (single dose); 12-17 h (long-term oral) | 2 h; 9 h (MHD) | 10 min (single dose); 1.5-2 h (continuous infusion) | 4 h | 5-6.5 h | 6.5 h |
| Bioavailability | 58%-85% | > 95% | 100% | 90% | 47%-60% | |
| Effect-onset time | 8-72 h | 1-3 h | 5 min (onset); 1 h (maintain) | Within 30 min (acute toothache); 5 h (maintain); 1 wk (diabetic neuropathy) | 24-28 h (repeated administration); no capping effect | |
| Metabolism | Liver | Liver | Liver (mainly) | Liver (less) | No metabolism in the body | |
| Excretion | Kidney (72%); Feces (28%) | Kidney (> 95%) | Kidney (mainly) | Kidney (92-99%) excreted as drug prototype | Kidney (mainly) excreted as drug prototype | |
Oxcarbazepine is a new type of anticonvulsant drug. It is a 10-keto derivative of carbamazepine. It mainly works through its active metabolite, 10- hydroxycarbamazepine (MHD). After taking a single dose of oxcarbazepine, the absorption time is 1 to 3 h, the peak serum concentration of its metabolite MHD is 4 h to 12 h, the protein binding rate of oxcarbazepine and MHD is 60% and 40%, and the t1/2 respectively is 1 to 5 h and 9 to 11 h[11]. Oxcarbazepine can be directly converted into the active metabolite MHD without P450 enzyme; therefore, the adverse effects of drugs and the drug interactions when combined are less. Oxcarbazepine and carbamazepine have different metabolic pathways in the liver via cytochrome P450 oxidase. Oxcarbazepine is reduced to MHD in the cytoplasm by reductase. MHD is not metabolized by the liver but excreted by the kidney. MHD’s steady-state levels can be reached within 2-3 d. Without liver drug enzyme induction and self-induction phenomenon and the blood drug concentration is nearly linear, making it easier to control the dose (Table 1).
The PKs of intravenous administration and transdermal lidocaine patch are very similar. About 70% of lidocaine binds to plasma proteins, mainly to α-1-acid glycoprotein. Lidocaine binds to plasma proteins in a concentration-dependent manner. It may pass through the placenta and the blood-brain barrier through passive diffusion. Lidocaine can be rapidly metabolized into a variety of metabolites in the liver with a bioavailability of about 35%. Metabolites include monomethyl glycerol dimethylaniline and glycine dimethylaniline. Their pharmacological effects are similar with lidocaine, but their activity is lower than lidocaine. Lidocaine and its metabolites are excreted by the kidneys. Less than 10% of lidocaine is excreted as its original form. When administered intravenously, lidocaine plasma clearance half-life is 81-149 min. Systemic clearance rate is 0.33-0.90 L/min (Table 1).
BLA classification is a diterpene diester, is a state-dependent sodium channel antagonist, no resistance and addiction, less adverse effects, is a potent analgesic and anti-inflammation agent. There are no studies of human PKs. After intravenous injection in rats and the blood drug-time curve appears to be an open three-compartment model. Its three-phase half-lives are: the fast-distribution phase half-life (t1/2 fast-distribution) = 2.87 min, distribution phase half-life (t1/2 distribution) = 11.6 min, elimination phase half-life (t1/2 elimination) = 5 h. In tissues, the concentrations in the liver and adrenal glands are highest, followed by the kidney, lung, spleen, and heart. The concentration in brain is lower, while in the brainstem is higher than in the cortex. After 4 h later of administration, the concentration in each organ was reduced by 50%. Within 6 d after administration, the amount of urine excretion accounted for 46% of the one intake, most of which is excreted within 21 h which is 82.3% of the total urine excretion. Exclusion from feces within 6 d accounted for 21.9% of one intake, and excretion from feces within 48 h accounted for 86.2% of total excretion from feces (Table 1).
Mechanisms of calcium channel modulators: Calcium ion channels play an important role in many physiological processes of the nervous system such as the regulation of excitability of neurons, the release of transmitters at synapse, synaptic plasticity, and gene transcription. These processes are achieved by regulating of calcium ion influx. Calcium channel modulators reduce the excitement of pain conduction pathways by inhibiting the influx of calcium ions and reducing the release of neurotransmitters, thereby achieving the purpose of pain relief[12].
Typical calcium channel modulators: Typical drugs of calcium channel modulators include gabapentin and pregabalin. Gabapentin was first used to control seizures and then was also used to treat NPP. Its structure is similar to that of GABA, but it does not work by binding with GABA receptors nor does it affect GABA synthesis and uptake. The voltage-gated calcium channel α2δ-1 subunit is the site of action of gabapentin. Specific binding can block the transport of α1 units of calcium channels from the cytoplasm to the cell membrane in dorsal root ganglia and spinal dorsal horn neurons. At the same time, the axoplasmic transport of the α2δ-1 subunit from the dorsal root ganglia to the spinal dorsal horn can also be blocked by gabapentin. Gabapentin can also inhibit the occurrence of pain through other sites such as transient receptor voltage channels, NMDA receptors, protein kinases, and inflammatory factors[13]. Similar to gabapentin, pregabalin blocks extracellular calcium ion influx in order to reduce the release of excitatory amino acids.
PKs, pharmacodynamic, and physicochemical characteristics of calcium channel antagonists: Gabapentin is mainly absorbed through the active transportation of amino acid transport systems in the intestine, and a ceiling effect occurs when saturated dose is reached. Oral gabapentin has high and dose-dependent bioavailability. Oral administration 300 mg need approximate 3 h to reach peak plasma at 2.7-2.99 mg/L. It can penetrate the blood-brain barrier, and the concentration of the drug in the cerebrospinal fluid can reach 9% to 14%[14] of the dosage after oral administration. Gabapentin has a distribution volume of about 0.6 to 0.8 L/kg and a half-life of about 6.5 h. The drug does not bind to plasma proteins, is not metabolized in the body, and is excreted from the kidneys as a prototype. Its clearance is consistent with creatinine clearance rate (CCR) (Table 1).
Pregabalin is an artificial synthetics compound by amino acid and natural neurotransmitter analogue, is water- and fat-soluble as well, easily cross the blood-brain barrier, and no GABA-like biological activity. Pregabalin is widely absorbed by the intestine after oral administration. It works within 30 min for acute toothache and sustains for 5 h. For diabetic neuropathy, onset time is about 1 wk after administration. The peak time of plasma concentration is about 1 h, and its absorption is fast and its therapeutic dose is non-linearly related to the plasma concentration. The bioavailability of pregabalin is 90%. Pregabalin is less metabolized in the liver; 92% to 99% of pregabalin is excreted by the kidney as a prototype and less than 0.1% of the oral amount is excreted with feces. The half-life is 5 to 6.5 h (Table 1).
Clinical indication: Carbamazepine and oxcarbazepine are the first choice for the treatment of glossopharyngeal neuralgia and trigeminal neuralgia (TN). The International Association for the Study of Pain, Neuropathic Pain Special Interest Group and other association’s guidelines and consensus have recommended carbamazepine and oxcarbazepine as first-line treatments for primary TN. Carbamazepine has also been recommended as the first-line treatment for glossopharyngeal neuralgia[15-19]. In addition to TN, it can also be used as a second-line medication for other NPPs such as diabetic peripheral neuropathy and postherpetic neuralgia (PHN)[20] (Table 2).
| Ref. | Year | Institution | Recommendations | |
| Sodium channel blockers | Calcium channel modulators | |||
| Finnerup et al[15] | 2016 | IASP | Topical use of lidocaine for PHN (first-line medication); Carbamazepine and oxcarbazepine for TN (first-line medication) | Gabapentin and pregabalin for NPP (first-line medication) |
| Attal et al[16] | 2010 | EFNS | Same with IASP (2010) | Gabapentin and pregabalin for diabetic neuralgia, PHN, central pain (first-line medication); Gabapentin not recommended for HIV neuralgia, post-traumatic neuralgia |
| CASP neuropathic pain treatment expert group[17] | 2013 | CASP | Same with IASP (2010); Bulleyaconitine A and lidocaine infusion is effective for NPP; Local anesthetics recommended for nerve block and intrathecal drug infusion | Same with IASP (2010) |
| Moulin et al[18] | 2014 | CPS | Topical use of lidocaine (second-line medication) | Same with IASP (2010) |
| Sumitani et al[19] | 2018 | JSPC | Carbamazepine for TN (first-line medication); Oxcarbazepine is not approved in Japan | Same with IASP (2010) |
Lidocaine is commonly used formulation is 2% injection and 5% cream/patch. Two percent lidocaine injection is mainly used for regional nerve block treatment. It was shown that intravenous infusion of low dose lidocaine has good analgesic effect for PHN, TN, complex regional pain syndrome (CRPS), diabetic peripheral neuropathy, tumor patients with radiotherapy and chemotherapy, peripheral neuralgia, cancer pain, fibromyalgia and other NPP[21,22].
Five percent lidocaine cream or patch is used to treat acute herpes zoster neuralgia and PHN, diabetic peripheral NPP, post-traumatic NPP, sunburn, or hyperalgesia caused by capsaicin. Topical lidocaine can be used as first-line treatment for herpes zoster-related neuralgia, and the commonly used formulation is lidocaine cream and patches. The U.S. Food and Drug Administration authorized 5% lidocaine patches may be used for zoster-related NPP. For persistent pain and allodynia caused by NPP not related to herpes, it is also effective, especially for later ones[23]. It is often recommended for peripheral NPP rather than central NPP. For secondary pain caused by central nervous system damage, intravenous lidocaine (5 mg/kg) is effective for specific pain and hyperalgesia.
BLA has good anti-inflammatory, analgesic and immunomodulatory effects. Currently, tablets and capsules are commonly used. Combined with opioids, it can reduce the dose of opioids and the incidence of adverse effects. It is widely used for the treatment of rheumatic immune disease, osteoarthritis, cancer pain, and other chronic pain diseases[24].
Administration and dosage: The recommended initial dose of carbamazepine for analgesia is 100 mg, twice per day. The maintenance dose is 400-800 mg/d, several times per day. The maximum dose is 1200 mg/d. The recommended initial dose of oxcarbazepine is 150 mg, twice per day, with a maintenance dose of 300-600 mg/d and a maximum dose of 1800 mg/d. Five percent lidocaine patch/cream is used for non-damaged skin, and its patch should cover the most painful areas. Five percent lidocaine patch can be used up to three patches at one time according to the prescribed amount, and the cumulative patch time within 24 h should not exceed 12 h. Five percent lidocaine cream is applied at 1.5-2.0 g/10 cm2. Most literature recommends intravenous lidocaine at 5 mg/kg, and the infusion time should not be less than 90 min[25]. The dosage of BLA is 0.4 mg capsules or tablets, one tablet (capsule), twice to three times per day.
Side effects and precautions: (1) Carbamazepine: It has a narrow treatment window and is prone to inducing adverse effects on many systems. Common side effects are blurred vision, dizziness, fatigue, nausea, and vomiting, which mostly occur after 1-2 wk of treatment. Rash, urticaria, liver dysfunction, and hypothyroidism are seldom. Granulocytopenia and bone marrow suppression, arrhythmia, liver, and kidney failure are rare. Guidance from the Clinical Pharmacogenetics Implementation Consortium[26] states that serious diseases such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis caused by carbamazepine are highly correlated with patients’ variant alleles human leukocyte antigen-B (HLA-B)*15:02 and HLA-A*31:01. Precaution: Carbamazepine treatment should be strictly evaluated by risk/benefit assessment, follow-up of patients with hematuria, liver and kidney function, and monitoring of plasma-concentration if possible. Attention should be paid to drug interactions with acetaminophen, digitalis, phenobarbital, erythromycin and so forth, and adverse effects should be treated in a timely manner. Attention should also be paid to hyperalgesia caused by carbamazepine withdrawal. At the same time, patients should be informed of the risk of SJS and toxic epidermal necrolysis before administration. HLA-B and HLA-A genotypes can be checked when conditions are warranted. HLA-B and HLA-A genotype information will provide evidence for drug selection.
(2) Oxcarbazepine: The most common adverse effects are rash, dizziness, headache, and drowsiness. The total incidence of adverse effects is 45.22%, most of which are mild and will alleviate or disappear after 3 to 4 wk. Oxcarbazepine does not affect liver drug enzyme metabolism and has linear PKs, and at the same time has less effects on cognitive function than barbiturates. Oxcarbazepine also can cause a severe rash, such as life-threatening SJS and toxic epidermal necrolysis, with a lower incidence than carbamazepine (1 to 6/10000 vs oxcarbazepine is 0.5 to 6/1000000)[27]. Unlike carbamazepine, the correlation between oxcarbazepine’s SJS or toxic epidermal necrolysis with HLA-B1502 has not been consistently reported[28].
(3) Side effects of intravenous lidocaine: Drowsiness, paresthesia, muscle tremor, convulsions, fainting, confusion and respiratory depression, hypotension, bradycardia, and other adverse effects. Extreme high blood concentration can cause slow atrial conduction velocity, atrioventricular block, and inhibit myocardial contractility and reduce cardiac output. Precautions of intravenous lidocaine: infusion should be in an environment with monitoring and rescue conditions. During the medication, blood pressure, electrocardiogram, and other vital signs should be monitored. The concentration, total dose, and rate of infusion should be strictly controlled. Lidocaine has slow metabolism and accumulation effect in the body, hence can cause poisoning and convulsions.
Side effects of the 5% lidocaine patch are moderate skin reactions such as erythema and rash. Even with three patches per day for 12 h or even four patches for 18 h, the blood concentration of lidocaine is still very low. However, the use of lidocaine patches should be avoided in patients with oral class I antiarrhythmic drugs such as mexiletine and patients with severe liver impairment. Lidocaine gel is effective in both herpes-related neuralgia and tactile pain and is ineffective against human immunodeficiency virus neuropathy. Patients who are allergic to amide local anesthetics or other ingredients in the product are contraindicated.
(4) BLA: No drug tolerance, no addiction, no gastrointestinal adverse effects. Very few patients may experience transient mild palpitation, nausea, numbness of the lips, and palpitations. The response is transient and can be relieved after stopping the treatment. Pregnant and lactating women, children, and those allergic to this product are prohibited. The interval between the two doses should be no less than 6 h.
Clinical indications: Indications for calcium channel modulators are mainly NPP including peripheral NPP such as herpes zoster neuralgia, diabetic peripheral neuralgia, CRPS, central NPP such as stroke pain, and pain after spinal cord injury. It is also considered a complementary treatment for cancer pain[29]. Gabapentin is commonly used in the treatment of herpes zoster neuralgia, diabetic painful neuropathy, cancerous pain, and TN. Pregabalin has good effects on the treatment of PHN, diabetic peripheral NPP, fibromyalgia, and others (Table 2).
Administration and dosage: Gabapentin usually starts at 300 mg daily, three times a day, and needs to be titrated slowly to an effective dose. The usual dose is 900-1800 mg per day. Pregabalin is a new-generation drug developed on the basis of gabapentin. The initial dose is 150 mg daily, twice daily, and the common dose is 150-600 mg per day. To avoid dizziness and drowsiness, you should follow the principle of the first dose at night, using a small amount, gradually increasing the amount, and slowly reducing it.
Drug side effects and precautions: (1) Common adverse effects of gabapentin include dizziness, drowsiness, ataxia, and peripheral edema. Symptoms of withdrawal include disturbance of consciousness, disorientation, non-specific gastrointestinal reactions, hyperhidrosis, tremor, etc. Precautions: Because it is excreted from the kidney as a prototype, patients with renal impairment should take reduced dose. Hemodialysis can accelerate the clearance of gabapentin, so patients with hemodialysis should take increased doses to maintain an effective concentration. There is no clear evidence that gabapentin can be used in pregnant women, and it is contraindicated in lactating women because the drug can be secreted through lactation.
(2) Pregabalin adverse effects include peripheral edema, PR interval extension, dizziness, somnolence, ataxia, headache metabolism, language barriers, tremors. Endocrine adverse effects are body weight increase, the occurrence rate is 4% to 12%; the muscular skeletal adverse effect is elevated creatine kinase levels, myoclonus and case-reported stripes muscle dissolution; pregabalin treatment occasionally causes liver enzyme transient increase with mild level, saliva deficiency, constipation, thrombocytopenia, blurred vision, diplopia, amblyopia, etc.[30]. Precautions: For patients with liver damage, there is no need to adjust the dosage. The recommended dose is applied for patients with CCR ≥ 60 mL/min. In cases of patients with renal dysfunction, the dose should be adjusted. For a patient undergoing hemodialysis treatment, the dose of pregabalin should be adjusted daily according to renal function. During treatment, patients should be monitored for depression, suicidal thoughts or behaviors, and any abnormal changes in mood or behavior.
The CASP organized first-line pain management experts from China to write an expert consensus as a reference for using ion channel drugs. Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, BLA, Pregabalin, and gabapentin. We hope this guideline provides direction for clinicians and patients when they use ion channel drugs for the management of NPP.
Manuscript source: Unsolicited manuscript
Specialty type: Anesthesiology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Xie KL S-Editor: Liu M L-Editor: Filipodia P-Editor: Liu JH
| 1. | Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC, Treede RD. A new definition of neuropathic pain. Pain. 2011;152:2204-2205. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 841] [Cited by in F6Publishing: 893] [Article Influence: 68.7] [Reference Citation Analysis (1)] |
| 2. | van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-662. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 799] [Cited by in F6Publishing: 995] [Article Influence: 90.5] [Reference Citation Analysis (0)] |
| 3. | Gierthmühlen J, Baron R. Neuropathic Pain. Semin Neurol. 2016;36:462-468. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 81] [Article Influence: 10.1] [Reference Citation Analysis (0)] |
| 4. | Rivara M, Zuliani V. Novel sodium channel antagonists in the treatment of neuropathic pain. Expert Opin Investig Drugs. 2016;25:215-226. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
| 5. | Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67:1265-1289. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 105] [Cited by in F6Publishing: 108] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 6. | Anderson GD, Saneto RP. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects. CNS Drugs. 2015;29:669-681. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 7. | Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008;58:280-286. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 79] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 8. | Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011;Jan 19:CD005451. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 45] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
| 9. | Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet. 1978;3:128-143. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 161] [Cited by in F6Publishing: 157] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
| 10. | Mazzucchelli I, Onat FY, Ozkara C, Atakli D, Specchio LM, Neve AL, Gatti G, Perucca E. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47:504-509. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 11. | May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42:1023-1042. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 164] [Cited by in F6Publishing: 166] [Article Influence: 8.3] [Reference Citation Analysis (0)] |
| 12. | Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-150. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 362] [Cited by in F6Publishing: 375] [Article Influence: 20.8] [Reference Citation Analysis (0)] |
| 13. | Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36:237-251. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 179] [Cited by in F6Publishing: 183] [Article Influence: 16.6] [Reference Citation Analysis (0)] |
| 14. | Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res. 1992;11:45-49. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
| 15. | Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157:1599-1606. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 593] [Cited by in F6Publishing: 747] [Article Influence: 106.7] [Reference Citation Analysis (0)] |
| 16. | Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-1e88. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1198] [Cited by in F6Publishing: 1137] [Article Influence: 81.2] [Reference Citation Analysis (0)] |
| 17. | CASP neuropathic pain treatment expert group. CASP Expert consensus on the treatment of neuropathic pain. Zhongguo Tengtong Yixue Zazhi. 2013;19:705-710. [Cited in This Article: ] |
| 18. | Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-335. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 343] [Cited by in F6Publishing: 325] [Article Influence: 32.5] [Reference Citation Analysis (0)] |
| 19. | Sumitani M, Sakai T, Matsuda Y, Abe H, Yamaguchi S, Hosokawa T, Fukui S. Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians. J Anesth. 2018;32:463-478. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
| 20. | Ghannoum M, Yates C, Galvao TF, Sowinski KM, Vo TH, Coogan A, Gosselin S, Lavergne V, Nolin TD, Hoffman RS; EXTRIP workgroup. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52:993-1004. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
| 21. | Schafranski MD, Malucelli T, Machado F, Takeshi H, Kaiber F, Schmidt C, Harth F. Intravenous lidocaine for fibromyalgia syndrome: an open trial. Clin Rheumatol. 2009;28:853-855. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
| 22. | Stavropoulou E, Argyra E, Zis P, Vadalouca A, Siafaka I. The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial. ISRN Pain. 2014;2014:853826. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 23. | Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2636] [Cited by in F6Publishing: 2374] [Article Influence: 263.8] [Reference Citation Analysis (0)] |
| 24. | Xie MX, Zhu HQ, Pang RP, Wen BT, Liu XG. Mechanisms for therapeutic effect of bulleyaconitine A on chronic pain. Mol Pain. 2018;14:1744806918797243. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 25. | Liu H, Lu F, Zhou D, Yin Y, Li J, Yang B, Song L, Ye L, Xiao H. The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. Clin J Pain. 2018;34:1025-1031. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 26. | Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018;103:574-581. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 145] [Cited by in F6Publishing: 170] [Article Influence: 28.3] [Reference Citation Analysis (0)] |
| 27. | Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017;12:CD007963. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
| 28. | Wei CY, Ko TM, Shen CY, Chen YT. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet. 2012;27:132-141. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 29. | Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111:105-111. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 175] [Cited by in F6Publishing: 190] [Article Influence: 17.3] [Reference Citation Analysis (0)] |
| 30. | Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 62] [Cited by in F6Publishing: 105] [Article Influence: 21.0] [Reference Citation Analysis (0)] |